GLP-1 for Migraine: The Exenatide IIH Trial + Stacking Evidence

Migraine affects roughly 12% of US adults and is strongly comorbid with obesity, especially in the chronic and high-frequency phenotypes (Bond 2011, Obesity Reviews^[6]). Two separate evidence streams put GLP-1 therapy on the migraine map. The IIH-Pressure trial (Mitchell 2023, Brain^[1]) showed exenatide reduced intracranial pressure by 5.7 cm H₂O at 12 weeks in idiopathic intracranial hypertension — an obesity-linked headache disorder. The Braca 2025 pilot in Headache^[2] added liraglutide to standard preventives in high-frequency and chronic migraine patients and reported a reduction of roughly 7–12 monthly migraine days, with the effect appearing well before substantial weight loss. This article walks through what the trials actually showed, the CGRP-class drug-interaction picture, and the practical stacking protocol for a migraine patient starting a GLP-1.

The honest summary

• The IIH evidence is the strongest. Mitchell 2023 (Brain^[1]) randomized adults with active idiopathic intracranial hypertension to exenatide or placebo and reported a 5.7 cm H₂O reduction in ICP at 12 weeks, independent of weight change. Headache day reduction tracked the ICP drop. The mechanism is GLP-1 receptor expression on choroid plexus epithelium.
• The migraine-specific evidence is pilot-stage. Braca 2025 (Headache^[2]) was an open-label prospective pilot of liraglutide as add-on in 31 patients with obesity plus high-frequency or chronic migraine on standard preventives. Mean monthly migraine days fell from ~20 at baseline by roughly 7–12 days at 12 weeks. The design cannot separate weight-loss effect from a direct GLP-1 effect, but the timing was fast.
• CGRP monoclonal antibodies do not interact. Aimovig (erenumab), Ajovy (fremanezumab), Emgality (galcanezumab), and Vyepti (eptinezumab) are large IgG-class biologics cleared by reticuloendothelial degradation, not CYP3A4 or gastric absorption. No GLP-1 PK interaction is expected.
• Oral gepants do interact, slightly. Calvarysky 2024 (Drug Safety^[7]) systematically reviewed GLP-1RA × oral drug interactions; the dominant mechanism is delayed gastric emptying lengthening time to peak plasma. For acute-use gepants and oral triptans, that means slower onset but largely preserved AUC.

What IIH-Pressure (Mitchell 2023) actually showed

The IIH-Pressure trial (Mitchell JL et al., 2023, Brain^[1]) is the first randomized controlled trial of any GLP-1 receptor agonist as a direct intracranial-pressure lowering agent. Sixteen women with active idiopathic intracranial hypertension were randomized 1:1 to subcutaneous exenatide twice daily or placebo for 12 weeks. The primary outcome was telemetric ICP measurement via an implanted Raumedic NEUROVENT-P sensor.

• ICP at 12 weeks: a reduction of 5.7 cm H₂O on exenatide vs placebo — statistically and clinically meaningful in a disease where 25–30 cm H₂O is the typical baseline.
• Headache day reduction: a parallel decline in monthly headache days that tracked the ICP fall.
• Weight independence: the ICP effect appeared at 2.5 hours after dosing and at 24 hours, before meaningful weight loss could explain it. The proposed mechanism is GLP-1 receptor signaling on choroid plexus epithelium reducing CSF secretion.

The Krajnc 2023 real-world cohort (Journal of Headache and Pain^[3]) and the Azzam 2025 propensity-matched analysis^[4] extended this signal: IIH patients treated with liraglutide had significantly greater weight loss and improved headache outcomes vs matched controls. The Halloum 2024 systematic review in the same journal^[4] aggregated the available data and concluded GLP-1RAs are a reasonable adjunct in IIH-driven headache.

The general migraine signal: Braca 2025 pilot

The first prospective trial of a GLP-1 specifically in migraine (not IIH) was Braca 2025 in Headache^[2]. Thirty-one patients with obesity and either high-frequency episodic migraine or chronic migraine, already on stable preventive therapy, were given liraglutide as add-on for 12 weeks. Mean monthly migraine days dropped substantially — the published reduction range is roughly 7–12 days from a high baseline of about 20 days per month. The effect emerged within the first 4 weeks, before any substantial weight loss, suggesting either a direct GLP-1 mechanism or a rapid response to small weight change.

The design has real limits: small sample, open-label, no placebo, single center. But the magnitude is large enough that it has triggered larger ongoing studies. Until those report, the Braca data should be read as hypothesis-generating for general migraine and as confirmation of the IIH-Pressure mechanism for the obesity-linked phenotype.

The obesity-migraine relationship

The Bond 2011 epidemiology review (Obesity Reviews^[6]) documented the dose-response between BMI and chronic migraine: obese adults have roughly 5x the prevalence of chronic migraine vs normal-weight adults, and severe obesity carries the highest risk. The companion Bond 2011 Neurology paper^[5] followed 24 severely obese adults through bariatric surgery and showed a substantial reduction in monthly migraine days at 6 months that tracked the weight loss curve.

The implication for GLP-1 patients: even without a direct GLP-1 receptor effect on migraine pathophysiology, a 15–22% body-weight reduction is itself a migraine-relevant intervention. The expected magnitude from the obesity-migraine literature is roughly 1–2 monthly migraine days lost per 5–10% weight loss, with larger effects in chronic and high-frequency phenotypes.

Magnitude: monthly migraine day reduction at 12 weeks

CGRP monoclonal antibodies: no GLP-1 interaction

The four FDA-approved CGRP-pathway monoclonal antibodies for migraine prevention are erenumab (Aimovig), fremanezumab (Ajovy), galcanezumab (Emgality), and eptinezumab (Vyepti). All four are large IgG-class biologics distributed in plasma and cleared by reticuloendothelial degradation. They have no oral absorption step, no CYP3A4 metabolism, and no gastric-emptying dependency.

That means a patient on Ajovy 225 mg monthly or Aimovig 140 mg monthly can start Wegovy, Zepbound, or Ozempic on the usual titration schedule without any PK adjustment to the CGRP biologic. Dosing days, sites, and route remain unchanged. The Calvarysky 2024 review^[7] includes no signal for monoclonal-antibody × GLP-1 interaction, consistent with the underlying pharmacology.

Eptinezumab (Vyepti) is given as an IV infusion every 3 months. Its administration logistics are independent of any oral or subcutaneous medication. The STRIVE trial of erenumab (Goadsby 2017, NEJM^[9]) and equivalent pivotal trials for the other three agents anchor the expected magnitude: roughly 1–3 monthly migraine day reduction at week 12 in episodic migraine.

Oral gepants: small PK effect, manageable

The small-molecule CGRP receptor antagonists — rimegepant (Nurtec ODT), ubrogepant (Ubrelvy), and atogepant (Qulipta) — are orally absorbed and rely on gastric emptying to reach peak plasma in 1–2 hours. Calvarysky 2024^[7] documented the class-level pattern: GLP-1 therapy slows gastric emptying enough to delay time-to-Cmax by 1–2 hours for many oral drugs, while overall AUC is largely preserved.

For atogepant used as a daily preventive (ADVANCE trial, Ailani 2021 NEJM^[8]), the small delay in onset is clinically irrelevant — steady-state plasma builds up over days. For rimegepant and ubrogepant used acutely, the delay matters more: a 1–2 hour shift in time-to-peak plasma may translate to a noticeable delay in headache relief. Patients who depend on rapid acute response should time the gepant 2 hours before or 2 hours after the GLP-1 dose, and should consider a non-oral acute option (sumatriptan nasal spray or subcutaneous injection) as backup on dose-day.

Triptans on a GLP-1

Oral triptans (sumatriptan tablet, rizatriptan, naratriptan, eletriptan) share the gastric-emptying-delayed onset issue with oral gepants. The class-level Calvarysky 2024 review^[7] did not single triptans out as high-risk, but the pharmacology predicts a 1–2 hour Cmax delay during active GLP-1 titration when gastric emptying is most slowed.

For patients with frequent acute attacks during GLP-1 dose escalation, the preferred routes bypass the gut entirely: sumatriptan subcutaneous injection (peak plasma in 10–15 minutes) or sumatriptan nasal spray. Both have Cmax onset that is independent of gastric motility and are unaffected by tirzepatide or semaglutide. Zolmitriptan nasal spray is the equivalent for patients who prefer it.

Topiramate stacking

Topiramate (Topamax) is a long-standing migraine preventive with weight-loss as a documented side effect — roughly 2–3% body weight reduction at 100–200 mg daily (Brandes 2004, JAMA^[10]). Co-prescribing topiramate and a GLP-1 produces additive weight loss but also additive cognitive blunting, paresthesias, and dysgeusia. Patients on chronic topiramate who add a GLP-1 should be monitored for word-finding difficulty and cognitive slowing; the threshold to taper one of the two should be lower than usual.

Phentermine-topiramate (Qsymia) plus a GLP-1 is a more aggressive combination occasionally used for super-obesity and treatment-resistant migraine; we cover the obesity-medicine framing in our broader stacking literature and would default to monotherapy whenever the migraine and weight-loss goals can be met by one agent.

The practical stacking protocol

1. Continue all migraine preventives at baseline dose. Do not taper Ajovy, Aimovig, Emgality, Vyepti, atogepant, or topiramate when starting a GLP-1. Re-evaluate at 6 months once both regimens are stable.
2. Time oral acute therapy around the GLP-1 dose. For Wegovy or Ozempic (weekly), the slowed-emptying window is roughly days 1–3 post-dose. Oral gepants and oral triptans taken during that window may take 1–2 hours longer to reach peak plasma. Schedule preventive atogepant for morning dosing regardless.
3. Stock a non-oral acute backup. Sumatriptan subcutaneous (Imitrex STATdose) or sumatriptan nasal spray is the recommended rescue route for patients with frequent acute attacks during GLP-1 titration. Zolmitriptan nasal spray is an alternative.
4. Track monthly migraine days. A simple paper or app-based diary with start of GLP-1 marked. Expect a 1–2 day reduction per 5–10% weight loss in the general obese-migraine population; expect a substantially larger reduction in patients with IIH features (papilledema, pulsatile tinnitus, elevated opening pressure on prior LP).
5. Screen for IIH if red flags are present. Headache worse on lying flat, transient visual obscurations, pulsatile tinnitus, or papilledema warrant ophthalmology referral with fundoscopic exam and consideration of neuro-imaging plus lumbar puncture. IIH-positive patients are the population in which GLP-1 therapy has the strongest headache-specific evidence (Mitchell 2023^[1]).
6. Re-evaluate at 6 months. If monthly migraine days have fallen substantially on the combined regimen, consider whether to de-escalate one preventive (typically topiramate first because of cognitive load) under headache-specialist supervision.

Insurance and access

CGRP-class migraine drugs are covered as specialty medications by most US commercial plans with prior authorization based on documented failed preventives. Manufacturer bridge programs (Aimovig Ally, Ajovy Patient Support, Emgality Persistence Program) often cover the first 12 months for commercially insured patients. GLP-1 therapy for migraine specifically is off-label — coverage runs through the usual obesity indication (BMI ≥ 30, or BMI ≥ 27 with a qualifying comorbidity) or Type 2 diabetes. There is no ICD-10 pathway for migraine-only GLP-1 coverage today.

Cost reference: oral gepants run roughly $1,000 per month retail; CGRP monoclonal antibodies $700–1,000 per month retail; brand-name GLP-1s $1,000–1,300 per month cash. Compounded semaglutide and tirzepatide via telehealth sit in the $200–400 per month range and are commonly used in non-IIH migraine patients who fail commercial-plan prior authorization for Wegovy or Zepbound.

Related research and tools

• GLP-1 brain fog and cognitive effects — the additive cognitive blunting concern when stacking GLP-1 with topiramate
• GLP-1 + SSRI interaction — SSRI-driven mood stabilization in migraine patients and gastric-emptying PK
• GLP-1 + statins interaction — the same gastric-emptying PK framework for a high-comorbidity class
• GLP-1 muscle loss prevention — the lean-mass protocol for migraine patients on combined regimens

Important disclaimer. This article is educational and does not constitute medical advice. Migraine management should be coordinated with a headache specialist or neurologist; idiopathic intracranial hypertension is a sight-threatening condition that requires ophthalmologic evaluation and is not a self-managed diagnosis. GLP-1 therapy for migraine is off-label; the strongest evidence is in the IIH subpopulation. Patients with a history of pancreatitis, medullary thyroid carcinoma, or MEN-2 should not use GLP-1 receptor agonists. PMIDs were verified live against the PubMed E-utilities API on 2026-05-29.

Last verified: 2026-05-29. Next review: every 12 months, or sooner if new randomized trial data on GLP-1 in migraine (post-Braca pilot extension or new sponsor trials) is published.